Daratumumab, a monoclonal antibody targeting CD38, has presented substantial efficacy as a monotherapy in heavily pretreated and refractory patients with MM and in conjunction with bortezomib in patients with NDMM as well as with IMiD in patients with RRMM. Here, CD38 is linked to Miyoshi myopathy.